Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management
22 Luglio 2009 - 2:00PM
PR Newswire (US)
Nationally Recognized Wound Specialist Dr. Robert J. Snyder to
Explore Potential of C'elle Menstrual Blood Stem Cells in Wound
Management and Limb Salvage Cryo-Cell International, Inc.
(OTC:CCEL) (BULLETIN BOARD: CCEL) , one of the largest and most
established leaders in stem cell innovation today announced a
research and development collaboration agreement with nationally
recognized wound specialist, Dr. Robert J. Snyder and the Snyder
Wound Research Institute LLC in Tamarac, FL. The partnership will
allow Dr. Snyder to conduct research studies using Cryo-Cell's
proprietary C'elle menstrual stem cell (MenSC) technology. The goal
of these collaborative efforts will be to identify and develop
potential future therapeutic applications for chronic wound
healing. Chronic wounds such as a leg ulcer from a vein problem, a
foot wound in a person with diabetes, or a bed sore, are wounds
that have a biological or physiological reason for not healing. It
is estimated that approximately 5.7 million patients in the U.S.
currently suffer from chronic wounds at an estimated cost of $20
billion annually, representing a significant burden to the U.S.
health care system including patients, practitioners and insurance
carriers. There are various types of chronic wounds and each has
its own causes and treatments. There are, for example,
approximately 20 million patients in this country with diabetes. It
is estimated that approximately fifteen percent of these patients
will develop an open sore, most commonly on the bottom of the foot,
referred to as a diabetic foot ulcer. These wounds are particularly
difficult to heal, impair the patient's quality of life and can
lead to serious complications, such as amputations and higher
mortality. This collaborative partnership will support an exciting
new area of research and development that will investigate the
potential benefits of new ways to utilize menstrual blood stem
cells in advanced therapeutic applications for wound management.
The scientific collaboration between Cryo-Cell and Dr. Snyder
presents an exciting opportunity to explore potential new protocols
that may possibly leverage the benefits of regenerative science to
advance new approaches to wound healing. "Our ability to understand
the science behind manipulating the chronic wound
micro-environment, in combination with the healing activity of stem
cells to discharge growth factors and encourage the formation of
new blood vessels in the patient, may possibly lead to innovative
breakthrough therapies," stated Dr. Snyder. "This research will
determine if the C'elle stem cells found in menstrual blood may
potentially mimic the wound healing process in therapeutic
applications, along with the added benefit of being both
non-invasive and cost-effective." "We are very pleased to partner
with Dr. Snyder to explore the utilization and potential
commercialization of Cryo-Cell's proprietary C'elle menstrual stem
cell technology in the future development of novel therapies for
healing chronic wounds," said Mercedes A. Walton, Cryo-Cell's
Chairman and CEO. "Millions of people worldwide may potentially
benefit from future stem cell therapies to treat debilitating
chronic wounds that can be life-impacting and devastating to
patients and their families." The C'elle service is based on
Cryo-Cell's expansive IP technology portfolio and was introduced in
November 2007 as the first and only service that empowers women to
collect and cryopreserve menstrual flow containing undifferentiated
adult stem cells for future utilization by the donor or possibly
first-degree relatives in a manner similar to umbilical cord blood
stem cells. Based on the continuing success of MenSCs in the
research setting, Cryo-Cell is actively expanding its portfolio of
research collaborations with world renowned scientists committed to
study this novel stem cell population for a broad range of
regenerative therapeutic development. About Robert J. Snyder,
D.P.M., C.W.S. In addition to treating patients in private
practice, Dr. Snyder serves as medical director of the Wound
Healing Center at University Hospital in Tamarac. Dr. Snyder is
board certified in foot and ankle surgery by the American Board of
Podiatric Surgery. He is a board certified wound specialist by the
American Academy of Wound Management and is president elect of that
organization. He is a fellow of the American College of Foot and
Ankle Surgeons, the American Professional Wound Care Association
and the College of Certified Wound Specialists. Dr. Snyder is also
an executive board member of the Association for the Advancement of
Wound Care. He was recently recognized in "Top 150 most influential
podiatrists in the United States" by Podiatry Management Magazine.
A frequent contributor to many medical journals, Dr. Snyder is
currently consulting editor for Podiatry Management Magazine and a
member of the editorial advisory boards of Ostomy Wound Management
and Wounds. He is a Clinical Professor (Adjunct) at Temple
University College of Podiatric Medicine and has authored over 100
papers for peer-reviewed and trade journals on topics relating to
wound management and limb salvage. Dr. Snyder has done extensive
research on many innovative wound care therapies. He is completing
an MSc in Wound Healing and Tissue Science at the Wales College of
Medicine, UK. About C'elle The C'elle(SM) service was introduced in
November 2007 as the first and only service that empowers women to
collect and cryopreserve menstrual flow containing undifferentiated
adult stem cells for future utilization by the donor or possibly
their first-degree relatives in a manner similar to umbilical cord
blood stem cells. For more information, visit http://www.celle.com/
About Cryo-Cell International, Inc. (OTCBB: CCEL.OB) Based in
Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell
is one of the largest and most established family cord blood banks.
ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell
operates in a state-of-the-art Good Manufacturing Practice and Good
Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a
publicly traded company. OTC Bulletin Board Symbol: CCEL. For more
information, please call 1-800-STOR-CELL (1-800-786-7235) or visit
http://www.cryo-cell.com/. Forward-Looking Statement Statements
wherein the terms "believes", "intends", "projects" or "expects" as
used are intended to reflect "forward-looking statements" of the
Company. The information contained herein is subject to various
risks, uncertainties and other factors that could cause actual
results to differ materially from the results anticipated in such
forward-looking statements or paragraphs, many of which are outside
the control of the Company. These uncertainties and other factors
include the uncertainty of market acceptance of any potential
service offerings relating to types of stem cells other than cord
blood stem cells, including the C'elle service, given that
menstrual stem cells and other new stem cells have not yet been
used in human therapies, and treatment applications using such stem
cells may not be developed and commercialized; or if they are not
likely to be developed or commercialized for many years and are
subject to further research and development; the need for
additional development and testing before determining the ultimate
commercial value of the Company's intellectual property relating to
the menstrual stem cells; the need to complete certain
developments, including completion of clinical validation and
testing, before any new process other than C'elle can be
commercialized, and the Company's development of its final business
and economic model in offering any such service; any adverse effect
or limitations caused by recent increases in government regulation
of stem cell storage facilities; any increased competition in our
business; any decrease or slowdown in the number of people seeking
to store stem cells or decrease in the number of people paying
annual storage fees; any technological breakthrough or medical
breakthrough that would render the Company's business of stem cell
preservation obsolete; and any other risk factors described in our
filing with the Securities and Exchange Commission. The foregoing
list is not exhaustive, and the Company disclaims any obligations
to subsequently revise any forward-looking statements to reflect
events or circumstances after the date of such statements. Readers
should also carefully review the risk factors described in other
documents the Company files from time to time with the Securities
and Exchange Commission, including the most recent Annual Report on
Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current
Reports on Form 8-K filed by the Company. Contact: General Media
Inquiries Kristin O'Neill 312-233-1295 Financial Media Inquiries:
Cryo-Cell International, Inc. Investor Relations Dianne Will
518-398-6222 DATASOURCE: Cryo-Cell International, Inc. CONTACT:
General Media, Kristin O'Neill, +1-312-233-1295, , for Cryo-Cell
International, Inc.; or Financial Media, Dianne Will of Cryo-Cell
International, Inc. Investor Relations, +1-518-398-6222, Web Site:
http://www.cryo-cell.com/ http://www.celle.com/
Copyright